Cost of acute hospitalization and post-discharge follow-up care for meningococcal disease in the United States

Human Vaccines

Volumn 7, Issue 1, 2011, Pages 96-101

  Davis, Keith L ^a   Misurski, Derek A ^b   Miller, Jacqueline M ^b   Bell, Timothy J ^b   Bapat, Bela ^a  

^a RTI HEALTH SOLUTIONS   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Administrative data; Hospital costs; Length of stay; Meningococcal disease; Post discharge costs

Indexed keywords

MENINGOCOCCUS VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHILD; CONTROLLED STUDY; COST OF ILLNESS; DISEASE CARRIER; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HOSPITAL COST; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; INFANT; INTENSIVE CARE UNIT; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCOSIS; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SCHOOL CHILD; UNITED STATES; VACCINATION;

EID: 79551710373     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.1.13692     Document Type: Article

References (18)

1. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med 2001; 344:1378-88.
2. Centers for Disease Control and Prevention. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2005; 54:1-21.
3. Centers for Disease Control and Prevention. Summary of notifiable diseases - United States 2003. MMWR Morb Mortal Wkly Rep 2005; 52:1-85.
4. Rosenstein NE, Perkins BA. Update on Haemophilus influenzae serotype b and meningococcal vaccines. Pediatr Clin North Am 2000; 47:337-52. (Pubitemid 30179944)
5. Centers for Disease Control and Prevention 2009. Active Bacterial Core Surveillance Report, Emerging Infections Program Network. Neisseria meningitidis 2008; http://www.cdc.gov/abcs/reports-findings/survreports/mening08.pdf.
6. Schuchat A, Robinson K, Wenger JD, Harrison LH, Farley M, Reingold AL, et al. Bacterial meningitis in the United States in 1995. N Engl J Med 1997; 337:970-6.
7. Dawson KG, Emerson JC, Burns JL. Fifteen years of experience with bacterial meningitis. Pediatr Infect Dis J 1999; 18:816-22. (Pubitemid 29428539)
8. Centers for Disease Control and Prevention 2001. Active Bacterial Core Surveillance Report, Emerging Infections Program Network. Neisseria meningitidis 2000; http://www.cdc.gov/abcs/reports-findings/survreports/mening00.pdf.
9. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, et al. Efficacy, safety and immunogenicity of heptavalent pneumonococcal conjugate vaccine in children. northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000; 19:187-95.
10. Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2000; 49:1-35.
11. American Academy of Pediatrics Committee on Infectious Diseases (AAPCID). Prevention and control of meningococcal disease: Recommendations for use of meningococcal vaccines in pediatric patients. Pediatrics 2005; 116:496-505.
12. Centers for Disease Control and Prevention. Meningococcal vaccines: what you need to know 2008. Available at: http://www.cdc.gov/vaccines/pubs/vis/ downloads/vis-mening.pdf. Accessed 9 September 2009.
13. O'Brien JA, Caro JJ, Getsios D. Managing meningococcal disease in the United States: hospital case characteristics and costs by age. Value Health 2006; 9:236-42.
14. Ortega-Sanchez IR, Meltzer MI, Shepard C, Zell E, Messonnier ML, Bilukha O, et al. Economics of an adolescent meningococcal conjugate vaccination catchup campaign in the United States. Clin Infect Dis 2008; 46:1-13. (Pubitemid 351263552)
15. O'Brien JA, Patrick AR, Caro JJ. Costs of managing CAP are double for elderly patients. Drug Benefit Trends 2003; 15:32-47.
16. Cohn AC, MacNeil JR, Harrison LH, Hatcher C, Theodore J, Schmidt M, et al. Changes in Neisseria meningitidis disease epidemiology in the United States 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010; 50:184-91.
17. Trotter CL, Maiden MC. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines 2009; 8:851-61.
18. Maiden MC, Ibarz-Pavón AB, Urwin R, Gray SJ, Andrews NJ, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008; 197:737-43. (Pubitemid 351364476)